Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer. Its current pipeline centers on antibody radiation conjugates and actinium-225-based programs designed to deliver radiation directly to tumor cells while limiting exposure to healthy tissue. The company’s lead product candidate, ATNM-400, is being developed as a multi-indication therapy for solid tumors including prostate cancer, non-small cell lung cancer, and breast cancer. Actinium is also advancing Actimab-A for hematologic malignancies such as acute myeloid leukemia, along with Iomab-ACT for conditioning before gene and cell therapies. Through these programs, Actinium Pharmaceuticals, Inc. plays a specialized role in precision oncology, addressing both solid tumor and blood cancer settings with radiopharmaceutical approaches.